The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the Society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy—from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for Immunotherapy of Cancer, an outlet devoted to and created by today's leaders in the field.
Less than a year after its first issue, JITC was accepted to PubMed and PubMed Central! This is an exciting step in the evolution of JITC, as it now offers greater visibility and accessibility to all accepted articles.
As a way to say thank you to the dedicated Society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer Society members waived article processing charges for manuscripts accepted in 2015. To take advantage of this member benefit, contact SITC at +1 414-271-2456 or firstname.lastname@example.org for your member code.
SITC will once again be offering two $1,000 USD awards for the best papers submitted in the Clinical/Translational and Basic Science categories. To be eligible, papers must be published in JITC by August 18, 2015.
Winners were announced at SITC's 29th Annual Meeting Award Ceremony on Saturday, November 8, 2014. Congratulations!
JITC Best Basic Science Paper Award
Stefani Spranger, PhD
University of Chicago
"Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment"
JITC Best Clinical Application Paper Award
Shailender Bhatia, MD
University of Washington
"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase I/II study"
Learn more about this year's award-winners' work, including what's next for their research in this Biome exclusive.
The journal welcomes submissions in the following areas and other related topics:
Basic Tumor Immunology
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation and response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy, interactions and/or combinations of chemotherapy and radiotherapy, oncolytic viruses, other combination treatments with the anti-tumor immune response
Reporting unusual or unexpected clinical cases that expand the field of general medical knowledge
Commentary as peer-reviewed reactions to significant events in the field, editorials as opinion pieces on ground-breaking news from the field, JITC and other outlets
Clinical/Translational Cancer Immunotherapy
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, updates on clinical trials
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies
Fact/data driven works that cumulate several articles of importance to the field in a review format
The Editorial Board is comprised of internationally recognized thought leaders in the field and experts in their content areas. They are also members of SITC and deeply committed to advancing the knowledge about, and integration of, cancer immunotherapy research into the clinical setting.